There are important reciprocal interactions between these infections. HIV has an important impact on the natural history of HCV liver disease. While spontaneous recovery from HCV occurs in approximately 15 to 30 percent of monoinfections, clearance occurs in only 5 to 10 percent of coinfections. 4 Likewise, among those with persistent HCV infection, HIV coinfection has been associated with a more rapid progression of fibrosis, cirrhosis, and possibly to hepatocellular carcinoma. [5] [6] [7] [8] HCV/HIV coinfection has a high rate of liver fibrosis progression, among different causes of end-stage liver disease. 9 In the pre-HAART era, the global relative risk of progression to liver cirrhosis or clinically apparent end-stage liver disease in HIV/HCV coinfected patients was 2.92 (95 percent confidence interval: 1.70 -5.01) when compared to HCV monoinfected patients. 10 Despite its potential hepatotoxicity, 11 HAART seems to modify the natural history of HCV infection. Coinfected patients who are protease inhibitor (PI)-experienced presented a lower fibrosis progression rate according to Benhamou et al. 12 Time under any kind of antiretroviral therapy is a protective factor for liver fibrosis in coinfected patients. 13 Other cofactors that are related to fibrosis progression in HCV alone, such as male sex, alcohol consumption, and duration of HCV infection also occur in HCV/HIV coinfected patients. 14 In the past, clinicians have been reluctant to offer HAART to coinfected patients. HAART-related hepatotoxicity is three to four times more frequent in HCV-or HBV-infected patients, and has an incidence of around 10 percent. 15 It is usually mild, and sometimes transient, but resolves with the discontinuation of therapy. An early reintroduction of another regimen is recommended, and no specific agent should be avoided, even though careful monitoring of liver enzymes is mandatory when antiretroviral therapy is started in coinfected patients.
On the other hand, it is important to stress the controversial impact that HCV infection has on the natural history of HIV and its response to HAART. Information from the Swiss cohort and from a recent study by de Luca et al 16, 17 pointed out an impairment of CD4 cell recovery and a risk of progression to AIDS in coinfected patients with the initiation of HAART. Conversely, Sulkowski et al 18 observed that HCV infection does not alter the risk of dying, developing AIDS, or responding to HAART. Results from the Aquitane cohort showed that severe transaminase elevation, rather than HCV infection itself was related with poorer survival in HIV-positive patients treated by HAART. 19 Therefore, several issues have to be considered in the clinical management of HCV/ HIV coinfected patients. Antiretroviral therapy should be strongly recommended in this setting because it may lower fibrosis progression. Lower prescription of antiretroviral therapy within that subset of patients has been associated with higher morbidity and mortality rates. 18 The indication for anti-HCV therapy has to be accurately evaluated, as it is less effective in coinfected patients, when compared to HCV monoinfected patients. 20, 21 There is also a strong concern about the occurrence of adverse events, especially depression, hair and weight loss, and a risk of lactic acidosis 22, 23 in patients who present an important background of mitochondrial toxicity related to a prolonged exposure to antiretroviral therapy. Moreover, HCV antiviral therapyrelated adverse events might have an impact on adherence to HAART. Therefore, to avoid toxicity and costs, it is important to establish early prognostic factors of viral response with measurement of viremia-at least in patients with genotype 1 or 4 where the treatment results are less encouraging. 24 Liver biopsy, which is currently under debate, 25, 26 should be performed in patients with predictors of poor response (such as genotype 1 and 4 or high baseline HCV viral load). It could become an efficient tool for advising patients about the risks and benefits of anti-HCV treatment.
Finally, liver transplantation is being investigated for the treatment of end-stage liver disease in HIV-positive patients, but poor availability and the need for tertiary healthcare facilities limit its practicality. Also, pharmacological interactions between necessary immune suppressors and protease inhibitors, 27 and the effect of immune suppressors on HIV stress the importance of starting therapy to prevent liver failure.
In summary, HAART and HCV antiviral therapy have become cornerstones in the increasingly complex clinical management of HCV/HIV coinfected patients. ■
